IGC Pharma Statistics

Total Valuation

IGC Pharma has a market cap or net worth of $25.38 million. The enterprise value is $25.21 million.

Market Cap	25.38M
Enterprise Value	25.21M

Important Dates

The next estimated earnings date is Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

IGC Pharma has 83.89 million shares outstanding. The number of shares has increased by 30.04% in one year.

Current Share Class	83.89M
Shares Outstanding	83.89M
Shares Change (YoY)	+30.04%
Shares Change (QoQ)	+2.52%
Owned by Insiders (%)	9.16%
Owned by Institutions (%)	24.42%
Float	76.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	18.21
Forward PS	18.35
PB Ratio	3.87
P/TBV Ratio	5.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	19.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.04.

Current Ratio	1.28
Quick Ratio	0.21
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -104.33% and return on invested capital (ROIC) is -65.39%.

Return on Equity (ROE)	-104.33%
Return on Assets (ROA)	-49.91%
Return on Invested Capital (ROIC)	-65.39%
Return on Capital Employed (ROCE)	-114.73%
Revenue Per Employee	$18,970
Profits Per Employee	-$106,284
Employee Count	67
Asset Turnover	0.14
Inventory Turnover	0.45

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.67% in the last 52 weeks. The beta is 1.45, so IGC Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.45
52-Week Price Change	-29.67%
50-Day Moving Average	0.31
200-Day Moving Average	0.33
Relative Strength Index (RSI)	46.37
Average Volume (20 Days)	232,098

Short Selling Information

The latest short interest is 525,944, so 0.63% of the outstanding shares have been sold short.

Short Interest	525,944
Short Previous Month	652,904
Short % of Shares Out	0.63%
Short % of Float	0.69%
Short Ratio (days to cover)	2.25

Income Statement

In the last 12 months, IGC Pharma had revenue of $1.27 million and -$7.12 million in losses. Loss per share was -$0.09.

Revenue	1.27M
Gross Profit	619,000
Operating Income	-7.45M
Pretax Income	-13.30M
Net Income	-7.12M
EBITDA	-6.83M
EBIT	-7.45M
Loss Per Share	-$0.09

Full Income Statement

Balance Sheet

The company has $405,000 in cash and $238,000 in debt, giving a net cash position of $167,000 or $0.00 per share.

Cash & Cash Equivalents	405,000
Total Debt	238,000
Net Cash	167,000
Net Cash Per Share	$0.00
Equity (Book Value)	6.33M
Book Value Per Share	0.08
Working Capital	639,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$4.80 million and capital expenditures -$112,000, giving a free cash flow of -$4.91 million.

Operating Cash Flow	-4.80M
Capital Expenditures	-112,000
Free Cash Flow	-4.91M
FCF Per Share	-$0.06

Full Cash Flow Statement

Margins

Gross Margin	48.70%
Operating Margin	-585.84%
Pretax Margin	-560.27%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IGC Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.04%
Shareholder Yield	n/a
Earnings Yield	-28.06%
FCF Yield	-19.34%

Analyst Forecast

The average price target for IGC Pharma is $3.88, which is 1,182.65% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.88
Price Target Difference	1,182.65%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 19, 2013. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Apr 19, 2013
Split Type	Reverse
Split Ratio	0.1:1

Scores

IGC Pharma has an Altman Z-Score of -14.54 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-14.54
Piotroski F-Score	3